|
|
|
Volumn 67, Issue 3, 2009, Pages 619-625
|
|
Recent progress in clinical trials for rheumatic diseases
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABATACEPT;
ANTIBODY CONJUGATE;
ANTIRHEUMATIC AGENT;
INTERLEUKIN 6;
JANUS KINASE 3;
METHOTREXATE;
MONOCLONAL ANTIBODY;
PROTEIN KINASE SYK;
PROTEIN TYROSINE KINASE;
RITUXIMAB;
SIGNAL PEPTIDE;
TUMOR NECROSIS FACTOR ALPHA;
CLINICAL TRIAL;
DRUG COMBINATION;
DRUG DESIGN;
HUMAN;
REVIEW;
RHEUMATIC DISEASE;
RHEUMATOID ARTHRITIS;
SIGNAL TRANSDUCTION;
SYSTEMIC LUPUS ERYTHEMATOSUS;
ANTIBODIES, MONOCLONAL;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
CLINICAL TRIALS AS TOPIC;
DRUG DESIGN;
DRUG THERAPY, COMBINATION;
HUMANS;
IMMUNOCONJUGATES;
INTERLEUKIN-6;
INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS;
JANUS KINASE 3;
LUPUS ERYTHEMATOSUS, SYSTEMIC;
METHOTREXATE;
PROTEIN-TYROSINE KINASES;
RHEUMATIC DISEASES;
SIGNAL TRANSDUCTION;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 65649100127
PISSN: 00471852
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (1)
|
|
References (15)
|
